0001999371-24-007198.txt : 20240606 0001999371-24-007198.hdr.sgml : 20240606 20240606112123 ACCESSION NUMBER: 0001999371-24-007198 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240606 ITEM INFORMATION: Material Modifications to Rights of Security Holders ITEM INFORMATION: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240606 DATE AS OF CHANGE: 20240606 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Tonix Pharmaceuticals Holding Corp. CENTRAL INDEX KEY: 0001430306 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 261434750 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36019 FILM NUMBER: 241024258 BUSINESS ADDRESS: STREET 1: 26 MAIN STREET, SUITE 101 CITY: CHATHAM STATE: NJ ZIP: 07928 BUSINESS PHONE: 212-980-9155 MAIL ADDRESS: STREET 1: 26 MAIN STREET, SUITE 101 CITY: CHATHAM STATE: NJ ZIP: 07928 FORMER COMPANY: FORMER CONFORMED NAME: TAMANDARE EXPLORATIONS INC. DATE OF NAME CHANGE: 20080320 8-K 1 tnxp_8k-060624.htm CURRENT REPORT Current Report
false --12-31 0001430306 0001430306 2024-06-06 2024-06-06 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
false 0001430306 0001430306 2024-06-06 2024-06-06 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
false 0001430306 0001430306 2024-06-06 2024-06-06 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES 

SECURITIES AND EXCHANGE COMMISSION 

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of report (date of earliest event reported): June 6, 2024

 

TONIX PHARMACEUTICALS HOLDING CORP. 

(Exact name of registrant as specified in its charter)

 

Nevada 001-36019 26-1434750

(State or Other Jurisdiction 

of Incorporation) 

(Commission 

File Number)

(IRS Employer 

Identification No.) 

 

26 Main Street, Chatham, New Jersey, 07928

(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code: (862) 904-8182

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) 

☐  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 

☐  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 

☐  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock TNXP The NASDAQ Capital Market

  

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). 

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ 

 

 

 

 

 

 

Item 3.03 Material Modification to Rights of Security Holders.

 

The Board of Directors of Tonix Pharmaceuticals Holding Corp., a Nevada corporation (the “Company”), has approved a reverse stock split of the Company’s issued and outstanding shares of common stock, par value $0.001 per share (the “Common Stock”), at a ratio of 1-for-32 (the “Reverse Stock Split”). The Company anticipates that the Reverse Stock Split will be effective at 12:01 a.m., Eastern Time, on June 10, 2024 (the “Effective Date”).

 

Reason for the Reverse Stock Split

 

The Company is effecting the Reverse Stock Split to satisfy the $1.00 minimum bid price requirement (the “Minimum Bid Price Requirement”), as set forth in Nasdaq Listing Rule 5550(a)(1) (the “Rule”), for continued listing on The NASDAQ Capital Market. As previously disclosed, on October 17, 2023, the Company received a letter from the staff of the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) indicating that for the last 30 consecutive business days, the closing bid price of the Company’s Common Stock had been below $1.00 per share, the minimum closing bid price required by Nasdaq Listing Rule 5450(a)(1) for continued listing on the NASDAQ Global Market. To regain compliance with the Rule, the closing bid price of the Company’s Common Stock must be at least $1.00 per share for a minimum of 10 consecutive business days.

 

Effects of the Reverse Stock Split

 

Effective Date; Symbol; CUSIP Number. The Reverse Stock Split becomes effective with NASDAQ and the Common Stock will begin trading on a split-adjusted basis at the open of business on the Effective Date. In connection with the Reverse Stock Split, the CUSIP number for the Common Stock will change to 890260847.

 

Split Adjustment; Treatment of Fractional Shares. On the Effective Date, the total number of shares of Common Stock held by each stockholder of the Company will be converted automatically into the number of shares of Common Stock equal to: (i) the number of issued and outstanding shares of Common Stock held by each such stockholder immediately prior to the Reverse Stock Split divided by (ii) 32. Any fractional share of Common Stock that would otherwise result from the Reverse Stock Split will be rounded up to a whole share and, as such, any stockholder who otherwise would have held a fractional share after giving effect to the Reverse Stock Split will instead hold one whole share of the post-Reverse Stock Split Common Stock after giving effect to the Reverse Stock Split. As a result, no fractional shares will be issued in connection with the Reverse Stock Split and no cash or other consideration will be paid in connection with any fractional shares that would otherwise have resulted from the Reverse Stock Split. The Company intends to treat stockholders holding shares of Common Stock in “street name” (that is, held through a bank, broker or other nominee) in the same manner as stockholders of record whose shares of Common Stock are registered in their names. Banks, brokers or other nominees will be instructed to effect the Reverse Stock Split for their beneficial holders holding shares of our Common Stock in “street name;” however, these banks, brokers or other nominees may apply their own specific procedures for processing the Reverse Stock Split.

 

Also on the Effective Date, all options, warrants and other convertible securities of the Company outstanding immediately prior to the Reverse Stock Split will be adjusted by dividing the number of shares of Common Stock into which the options, warrants and other convertible securities are exercisable or convertible by 32 and multiplying the exercise or conversion price thereof by 32, all in accordance with the terms of the plans, agreements or arrangements governing such options, warrants and other convertible securities and subject to rounding to the nearest whole share. Such proportional adjustments will also be made to the number of shares and restricted stock units issued and issuable under the Company’s equity compensation plan.

 

Certificated and Non-Certificated Shares. Stockholders who hold their shares in electronic form at brokerage firms do not need to take any action, as the effect of the Reverse Stock Split will automatically be reflected in their brokerage accounts.

 

Stockholders holding paper certificates may (but are not required to) send the certificates to the Company’s transfer agent and registrar, vStock Transfer, LLC (“vStock”), at the address set forth below. vStock will issue a new stock certificate reflecting the Reverse Stock Split to each requesting stockholder. VStock can be contacted at (212) 828-8436.

 

vStock Transfer, LLC

18 Lafayette Place

Woodmere, NY 11598

 

 

 

 

No Charter Amendment. Under Nevada law, no amendment to the Company’s Articles of Incorporation is required in connection with the Reverse Stock Split.

 

Stockholder Approval. Under the Nevada Revised Statutes (“NRS”) 78.2055, which was amended by the Nevada Legislature in 2023 pursuant to Assembly Bill No. 126, a publicly traded corporation, as defined in NRS 78.010(1)(e), may decrease the number of issued and outstanding shares of a class or series without correspondingly decreasing the number of authorized shares of the same class or series if: (a) the board of directors adopts a resolution setting forth the proposal to decrease the number of issued and outstanding shares of a class or series; and (b) the proposal is approved by a vote of the stockholders of the affected class or series. The Reverse Stock Split was approved pursuant to NRS 78.2055, as amended, by the Company’s stockholders on May 22, 2024, and accordingly will not have any effect on the number of authorized shares of Common Stock.

 

Capitalization. The number of authorized shares of Common Stock was and will remain at 1,000,000,000 following the Reverse Stock Split. As of June 5, 2024 there were 95,543,805 shares of Common Stock outstanding. As a result of the Reverse Stock Split, there will be approximately 2,985,744 shares of Common Stock outstanding (subject to adjustment due to the effect of rounding fractional shares into whole shares). The Reverse Stock Split will not have any effect on number of authorized shares of Common Stock or the stated par value of the Common Stock.

 

The Reverse Stock Split does not affect the Company’s authorized preferred stock. There are no outstanding shares of the Company’s preferred stock. After the Reverse Stock Split, the Company’s authorized preferred Stock of 5,000,000 shares will remain unchanged.

 

Immediately following the Reverse Stock Split, each stockholder’s relative ownership interest in the Company and proportional voting power will remain virtually unchanged except for minor changes and adjustments that will result from rounding fractional shares into whole shares.

 

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

 

The information set forth in Item 3.03 of this Current Report on Form 8-K is hereby incorporated by reference into this Item 5.03.

 

Item 8.01 Other Events.

 

On June 6, 2024, the Company issued a press release announcing the Reverse Stock Split. A copy of the press release is attached hereto as Exhibit 99.01 to this Current Report on Form 8-K and is incorporated herein by reference.

 

Forward- Looking Statements

 

This Current Report on Form 8-K contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Reverse Stock Split, the Company’s product development, clinical trials, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions.

 

These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the SEC. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

 

Item 9.01 Financial Statements and Exhibits.

 

(d)  

Exhibit

No.

   Description.
   

99.01

104

  

Press Release of the Company, dated June 6, 2024

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

SIGNATURE

 

Pursuant to the requirement of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  TONIX PHARMACEUTICALS HOLDING CORP.
   
Date: June 6, 2024 By: /s/ Bradley Saenger  
  Bradley Saenger
  Chief Financial Officer

 

 

 

 EX-99.01 2 ex99-01.htm PRESS RELEASE

 

 

TONIX PHARMACEUTICALS HOLDING CORP. 8-K

EXHIBIT 99.01

 

Tonix Pharmaceuticals Announces 1-for-32 Reverse Stock Split

 

CHATHAM, N.J., June 6, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that it will effect a 1-for-32 reverse stock split of its outstanding common stock. The reverse stock split will be effective for trading purposes as of the commencement of trading on June 10, 2024.

 

The reverse stock split is intended to increase the per share trading price of Tonix’s common stock to satisfy the $1.00 minimum bid price requirement for continued listing on The NASDAQ Capital Market (Rule 5550(a)(1)). Tonix’s common stock will continue to trade on the NASDAQ Capital Market under the symbol “TNXP” and under a new CUSIP number, 890260 847. As a result of the reverse stock split, every thirty-two pre-split shares of common stock outstanding will become one share of common stock. The reverse split will also apply to common stock issuable upon the exercise of Tonix’s outstanding warrants and stock options. The reverse stock split will not proportionately reduce the number of shares of authorized common stock, as permitted under Nevada law, as shareholder approval for the reverse stock split was obtained on May 22, 2024.

 

Tonix’s transfer agent, VStock Transfer LLC, which is also acting as the exchange agent for the reverse split, will provide instructions to shareholders regarding the process for exchanging share certificates. Any fractional shares of common stock resulting from the reverse stock split will be rounded up to the nearest whole post-split share and no shareholders will receive cash in lieu of fractional shares.

 

Tonix Pharmaceuticals Holding Corp.*

 

Tonix is a fully-integrated biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix’s development portfolio is focused on central nervous system (CNS) disorders. Tonix’s priority is to submit a New Drug Application (NDA) to the FDA in the second half of 2024 for Tonmya, a product candidate for which two positive Phase 3 studies have been completed for the management of fibromyalgia. TNX-102 SL is also being developed to treat acute stress reaction as well as fibromyalgia-type Long COVID. Tonix’s CNS portfolio includes TNX-1300 (cocaine esterase) a biologic designed to treat cocaine intoxication with Breakthrough Therapy designation. Tonix’s immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease. Tonix Medicines, our commercial subsidiary, markets Zembrace® SymTouch® (sumatriptan injection) 3 mg and Tosymra® (sumatriptan nasal spray) 10 mg for the treatment of acute migraine with or without aura in adults.

 

*Tonix’s product development candidates are investigational new drugs or biologics and have not been approved for any indication.

 

Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. All other marks are property of their respective owners.

 

This press release and further information about Tonix can be found at www.tonixpharma.com.

 

 

 

 

Forward Looking Statements

 

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Tonix's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; risks related to the failure to successfully market any of our products; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the Securities and Exchange Commission (the “SEC”) on April 1, 2024, and periodic reports filed with the SEC on or after the date thereof. All of Tonix's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.

 

Investor Contact

 

Jessica Morris

 

Tonix Pharmaceuticals

 

investor.relations@tonixpharma.com

 

(862) 904-8182

 

Peter Vozzo

 

ICR Westwicke

 

peter.vozzo@westwicke.com

 

(443) 213-0505

 

 

Media Contact

 

Katie Dodge

 

LaVoieHealthScience

 

kdodge@lavoiehealthscience.com

 

(978) 360-3151

 

 

 

 EX-101.SCH 3 tnxp-20240606.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 tnxp-20240606_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 5 tnxp-20240606_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 tnxp-20240606_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 8 R1.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Cover
Jun. 06, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jun. 06, 2024
Current Fiscal Year End Date --12-31
Entity File Number 001-36019
Entity Registrant Name TONIX PHARMACEUTICALS HOLDING CORP.
Entity Central Index Key 0001430306
Entity Tax Identification Number 26-1434750
Entity Incorporation, State or Country Code NV
Entity Address, Address Line One 26 Main Street
Entity Address, City or Town Chatham
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 07928
City Area Code (862)
Local Phone Number 904-8182
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol TNXP
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.1.u2 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://tonixpharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tnxp-20240606.xsd tnxp-20240606_lab.xml tnxp-20240606_pre.xml tnxp_8k-060624.htm http://xbrl.sec.gov/dei/2024 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tnxp_8k-060624.htm": { "nsprefix": "TNXP", "nsuri": "http://tonixpharma.com/20240606", "dts": { "schema": { "local": [ "tnxp-20240606.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] }, "labelLink": { "local": [ "tnxp-20240606_lab.xml" ] }, "presentationLink": { "local": [ "tnxp-20240606_pre.xml" ] }, "inline": { "local": [ "tnxp_8k-060624.htm" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 3, "http://xbrl.sec.gov/dei/2024": 3 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2024": 23 }, "report": { "R1": { "role": "http://tonixpharma.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-06-06", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "tnxp_8k-060624.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-06-06", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "tnxp_8k-060624.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentDescription", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AnnualInformationForm", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CountryRegion", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAccountingStandard", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAnnualReport", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodStartDate", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentRegistrationStatement", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyReport", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine3", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCountry", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPrimarySicNumber", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityVoluntaryFilers", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Extension", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NoTradingSymbolFlag", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12gTitle", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityReportingObligation", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 16 0001999371-24-007198-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001999371-24-007198-xbrl.zip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end XML 18 tnxp_8k-060624_htm.xml IDEA: XBRL DOCUMENT 0001430306 2024-06-06 2024-06-06 iso4217:USD shares iso4217:USD shares false --12-31 0001430306 8-K 2024-06-06 TONIX PHARMACEUTICALS HOLDING CORP. NV 001-36019 26-1434750 26 Main Street Chatham NJ 07928 (862) 904-8182 false false false false Common Stock TNXP NASDAQ false